The journey of bringing bio-based technologies from the lab to the market is anything but easy, and having a trusted guide can make all the difference. 𝐖𝐞 𝐚𝐫𝐞 𝐭𝐡𝐫𝐢𝐥𝐥𝐞𝐝 𝐭𝐨 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐭𝐡𝐞 𝐚𝐝𝐝𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐟𝐢𝐯𝐞 𝐧𝐞𝐰 𝐯𝐞𝐧𝐭𝐮𝐫𝐞 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬 𝐭𝐨 𝐨𝐮𝐫 𝐭𝐞𝐚𝐦! These industry experts will support Breakout, our portfolio, and our broader ecosystem — from diligencing investment opportunities to commercializing new tech. 𝐏𝐥𝐞𝐚𝐬𝐞 𝐣𝐨𝐢𝐧 𝐮𝐬 𝐢𝐧 𝐰𝐞𝐥𝐜𝐨𝐦𝐢𝐧𝐠: ✨ Sridhar Iyengar, PhD: Founder and Chief Strategy Officer of Elemental Machines ✨ Coco Krumme, PhD: Founder of Leeward Co ✨ Rebecca Nugent, PhD: VP of HTP Operations at Tessera Therapeutics ✨ Walter Solomon: Board Director and Advisor ✨ Ilan Zipkin, PhD: Founder and CEO of Supercede Therapeutics, Inc. Breakout Ventures is built on the theory that creative bioscience founders need more than just capital to take on the world's biggest challenges in human health and sustainability. Thank you to our venture partners, advisors, and community members for helping us build a bio-based future! 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐫𝐞𝐥𝐞𝐚𝐬𝐞: https://lnkd.in/gp4SADTe
Breakout Ventures
Venture Capital and Private Equity Principals
Building a future powered by science.
About us
Breakout Ventures is the home for creative bioscience entrepreneurs. We invest in early stage companies harnessing the power of cells to build solutions in human health and sustainability. Our team has spent the last decade supporting science-driven companies moving with urgency. We partner with bold founders throughout the entire life cycle, from seed to scale. Our portfolio has grown leather without the cow, reprogrammed B cells to produce personalized protein therapeutics, and transformed industrial carbon dioxide emissions into useful products. We believe cells are the engine of the next decade as the tools, technologies and, most importantly, talent from across industries are brought to bear on biology and chemistry in surprising ways. Breakout Ventures, building the future powered by science.
- Website
-
http://www.breakout.vc
External link for Breakout Ventures
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Headquarters
- San Francisco
- Type
- Partnership
- Founded
- 2016
- Specialties
- Technology, Science, Deep Technology, Therapeutics, Sustainability, Human Health, Diagnostics, Biomanufacturing, Materials, Decarbonization, Cell Engineering, Neuro, Biomaterials, Waste Conversion, biochemicals, Genomics, Proteomics, Gene Therapy, Cell Therapy, Petroleum product replacement, and
Locations
-
Primary
San Francisco, US
Employees at Breakout Ventures
-
Lindy Morris Fishburne
Managing Partner, Breakout Ventures
-
Julia Moore
Co-Founder and Managing Partner at Breakout Ventures
-
Asmi Chakraborty, PhD
Industry Strategy and Investments @MLSC | Business Development | Innovation Commercialization
-
Susanna Harris, PhD
Helping Scientists Communicate
Updates
-
NOETIK has officially joined an elite group of 80 start-ups worldwide for the 2024 cohort of the Amazon Web Services (AWS) Generative AI Accelerator! 𝐍𝐞𝐰𝐬 𝐚𝐭 𝐚 𝐠𝐥𝐚𝐧𝐜𝐞: 🧬 Breakout Ventures' portfolio company NOETIK is an AI-native biotechnology company developing next-generation cancer immunotherapies by combining machine learning with high-throughput biological data. 💵 As a 2024 cohort member, NOETIK will receive $1 million in AWS credits, working alongside AI giants like NVIDIA, Mistral AI, and Meta. 🏆 The AWS Generative AI Accelerator initiative is part of Amazon Web Services (AWS)'s $230 million commitment to driving innovation in the generative AI space, with <2% of applicants chosen each year. 𝐑𝐞𝐚𝐝 The Washington Post 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: https://lnkd.in/dWpnsa9C
Startups shaping the future of generative AI
washingtonpost.com
-
Exciting 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥 𝐧𝐞𝐰𝐬 from Incendia Therapeutics! The Breakout Ventures portfolio company has initiated the Phase Ic trial of their groundbreaking DDR1 inhibitor to target metastatic solid tumors. 𝐍𝐞𝐰𝐬 𝐚𝐭 𝐚 𝐠𝐥𝐚𝐧𝐜𝐞: 🔬 Incendia Therapeutics' PRTH-101 targets collagen-binding protein DDR1 to disrupt tumor collagen alignment, allowing immune cell access into the tumor core. 🧫 High DDR1-associated collagen barriers are present in cancers like thymic, colorectal, pancreatic, ovarian, non-small cell lung cancer, and glioma. 💊 The trial will enroll up to 270 patients to evaluate the safety, tolerability, dosing, and anti-tumor activity of PRTH-101, which will be tested as a monotherapy and in combination with Merck's Keytruda. Keep an eye out for future updates - this study paves the way for future Phase II/III trials, with global feasibility already underway. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 Precision Medicine Online 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: https://lnkd.in/d4Z5MG_D 𝐑𝐞𝐚𝐝 Incendia Therapeutics' 𝐫𝐞𝐥𝐞𝐚𝐬𝐞: https://lnkd.in/dFZ3wBMi
Incendia Therapeutics' DDR1 Inhibitor Advances to Phase Ic Trial
precisionmedicineonline.com
-
The world's fossil fuel problem can't be solved by switching to EVs - from cosmetics to clothing, your home is probably 𝘧𝘶𝘭𝘭 of petrochemicals. ZymoChem has a plan to fix it. 𝐒𝐭𝐨𝐫𝐲 𝐚𝐭 𝐚 𝐠𝐥𝐚𝐧𝐜𝐞: 🌿 Using carbon-conserving microbes, ZymoChem produces sustainable bio-based alternatives to petrochemicals with near-zero CO₂ emissions and up to 50% higher yield than conventional methods. 🛁 ZymoChem's BAYSE Bio-Sap is a 100% biodegradable super absorbent polymer that can drop into existing manufacturing systems for consumer hygiene products, agriculture, cosmetics, and more. 💸 With financing from their recent $21M Series A and funding from the United States Department of Defense, ZymoChem is partnering with leaders like lululemon and Toyota Ventures to create a real-zero economy. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 Springwise 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: https://lnkd.in/d-UqPr45
Fermenting feedstocks into everyday products - Springwise
springwise.com
-
The Neurostimulation Devices industry is set to experience a huge surge, with the market forecasted to expand from $7.3 billion in 2023 to $12.5 billion by 2030. ShiraTronics, Inc. is ready to fill that need. 𝐒𝐭𝐨𝐫𝐲 𝐚𝐭 𝐚 𝐠𝐥𝐚𝐧𝐜𝐞: 📈 Per For insight consultancy's "Neurostimulation Devices Market Forecast to 2030” report, the market for neurostimulation devices is expected to grow rapidly at 8.5% CAGR. 💼 The report took into account the 6 year financial and strategic development performance of several market leaders, including Breakout's portfolio company ShiraTronics, Inc., as well as Medtronic, BD, LivaNova, and Axonics, Inc. 📝 A free sample of the report is available by request: https://lnkd.in/dePEzU_Y 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: https://lnkd.in/dSKcxFRe
Neurostimulation Devices Industry Trends is Electrifying Growth Cycle : Medtronic, BD, LivaNova, Axonics, ShiraTronics
https://www.dailynewsmirror.in
-
Sepsis is more deadly than heart attacks and strokes 𝘤𝘰𝘮𝘣𝘪𝘯𝘦𝘥. Now, more hospitals are making the switch to Cytovale's diagnostic tool to speed their process of saving lives. 𝐍𝐞𝐰𝐬 𝐚𝐭 𝐚 𝐠𝐥𝐚𝐧𝐜𝐞: 🏥 St. Dominic Hospital, part of the Franciscan Missionaries of Our Lady Health System, is extending access to the IntelliSep test throughout Louisiana and Mississippi. 🚑 Cytovale's FDA-cleared IntelliSep diagnostic tool provides results in just 8 minutes, helping emergency departments quickly and accurately assess patients' risk of sepsis - reducing mortality rates by up to 30% and saving an average of nearly $1,500 per patient. 👨⚕️ As said by Jeremy Tinnerello RN, MSN, MHA, CEN, President at St. Dominic Hospital and FMOL HEALTH SYSTEMS, "Having started my career as an ER nurse, I've witnessed firsthand the impact of diagnosing sepsis early and the importance early treatment has on patient outcomes." 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐬𝐭𝐨𝐫𝐲 𝐨𝐧 Yahoo Finance https://lnkd.in/dgzjV2uV
St. Dominic's Leads Healthcare Innovation in Mississippi with Groundbreaking Sepsis Detection Technology
finance.yahoo.com
-
We're thrilled to co-host this year's RISE Celebration networking event with UCSF Rosenman Institute! Looking forward to meeting the 2024 cohort and learning how we can work to shape the future of healthcare.
Are you looking to network with investors and make rich connections for your healthcare technology startup? At this invite only RISE networking event, we will be celebrating the next generation of healthcare leaders! We are excited this event is co-hosted by: Breakout Ventures, Civilization Ventures, Creative Ventures, Emerson Collective, Foothill Ventures, Medical Technology Venture Partners, American Heart Association Social Impact Fund, Vive Collective, MedMountain Ventures, and sponsored by Perkins Coie. Apply to attend: https://lnkd.in/gyeMe3gH
-
Heading to BioVentures Nexus in October? Be sure to connect with our Venture Partner, Rebecca Nugent, to learn how Breakout thinks about synthetic biology and what catches our eye in biotech!
Thrilled to be representing Breakout Ventures at BioVenture Nexus 2024 on October 3-4 at the JW Marriott - The Ritz Carlton, Los Angeles! This is the event for anyone serious about Biotech, Synthetic Biology, AI in bio, Life sciences, Food Tech, AgriTech, Climate Tech, and beyond. Can't wait to share insights and connect with top innovators, VCs, and decision-makers! Join us and be part of the future! https://lnkd.in/gzrjsfeV #BioVentureNexus2024 #Innovation #VC #Startups #Biotech #SyntheticBiology #AI #LifeSciences #Networking #AgriTech #ClimateTech
Bioventure nexus
bioventurenexus.com
-
Breakout Ventures reposted this
Fantastic write-up by Breakout Ventures' own Nima Ronaghi, PhD announcing our investment in NOETIK. Thrilled to work with Ron Alfa, MD, PhD, Jacob Rinaldi, Lacey Padrón and Shafique Virani, MD FRCS and couldn't imagine a better partnership to come together than this investor crew (co-investors James Hardiman, Dylan Reid, Manik Kuchroo, and Amy Schulman). And as Nima writes Noetik team — it is a privilege to be "beautifully impatient" alongside you.
Thrilled to share our article detailing why Breakout Ventures invested in NOETIK, a company revolutionizing cancer treatment via AI-driven precision immunotherapies! TLDR: Traditional cancer treatments often fail due to the complexity of tumor microenvironments – a perfect problem for advanced machine learning to tackle. Noetik’s platform leverages self-supervised machine learning to profile real patient data, uncovering the biology of cancer at a level we have only dreamed of until this point. Ron Alfa, MD, PhD, Jacob Rinaldi, Lacey Padrón, Shafique Virani, MD FRCS and the Noetik team have raised $40M to turn this data into advanced precision cancer therapies. The round was led by Polaris Partners, and also included participation from DCVC, Khosla Ventures, Zetta Venture Partners, and Wittington Ventures. Special thanks to Julia Moore and Susanna Harris, PhD for their help with editing - y'all rock! Check out the full Medium article and let me know what you think: https://lnkd.in/gM59JdzC
Multimodal AI for Precision Immunotherapy
medium.com
-
Breakout Ventures reposted this
Amazing combination of both team and technology!
We're thrilled to share that we've invested in NOETIK, a startup using AI to generate precision immunotherapies! Our own Nima Ronaghi, PhD explains 𝒘𝒉𝒚 on Medium. 𝐒𝐭𝐨𝐫𝐲 𝐚𝐭 𝐚 𝐠𝐥𝐚𝐧𝐜𝐞: 🏥 Traditional “one-size-fits-all” cancer treatments often fall short thanks to the complexity of tumor microenvironments, which can vary drastically from patient to patient. 🧬NOETIK’s platform uses self-supervised machine learning to profile the histology, genomics, and spatial data of real patient samples. By digitizing human tumor biology, the team is discovering and developing the next generation of precision cancer immunotherapies. 🥇 NOETIK is led by an unparalleled team of co-founders: Ron Alfa, MD, PhD, Jacob Rinaldi, CTO Lacey Padrón, and CBO Shafique Virani, MD FRCS. 💸 As covered by Andrew Dunn at Endpoints News (https://lnkd.in/dPmvtn_j), NOETIK’s $40M Series A round was led by Polaris Partners, with participation from Breakout Ventures, Khosla Ventures, Wittington Ventures, DCVC, Zetta Venture Partners, Catalio Capital Management, 11.2 Capital, EPIC Ventures, Intermountain Ventures, and North South Ventures. Breakout Ventures is proud to partner with Noetik as they revolutionize cancer treatment and lead the charge in intelligent biosciences. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐨𝐧 𝐌𝐞𝐝𝐢𝐮𝐦: https://lnkd.in/d6CTDg8b Thank you to Julia Moore (Breakout’s Managing Partner and Co-Founder) and Susanna Harris, PhD (our Director of Community) for editing. #Immunotherapy #MachineLearning #Oncology #PrecisionMedicine #Biotechnology
Multimodal AI for Precision Immunotherapy
medium.com